High-dose olanzapine in treatment-resistant schizophrenia: a systematic review

BACKGROUND: Treatment-resistant schizophrenia (TRS) affects approximately 30% of people with schizophrenia. Clozapine is the gold standard treatment for TRS but is not always suitable, with a proportion of individuals intolerant of side effects or unable to engage in necessary blood monitoring. Give...

Descripción completa

Detalles Bibliográficos
Autores principales: Gannon, Louisa, Reynolds, John, Mahon, Martin, Gaughran, Fiona, Lally, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176543/
https://www.ncbi.nlm.nih.gov/pubmed/37187727
http://dx.doi.org/10.1177/20451253231168788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176543/
https://www.ncbi.nlm.nih.gov/pubmed/37187727
http://dx.doi.org/10.1177/20451253231168788

Ejemplares similares